As a tumor suppressor, IGFBP7 can protect patients against bone disease in cases of multiple myeloma and overcome activin A-induced osteoblast suppression along with promoting osteogenesis in vitro (Bolomsky et al., 2015). The gene discussed is IGFBP7; the disease is plasma cell myeloma.